TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~- Patients who have completed selected ongoing or planned trials with FTY720.~Key Exclusion Criteria:~* Premature permanent discontinuation of a previous fingolimod study.~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential, UNLESS they are using two birth control methods, at least 1 of which must be hormonal contraception, tubal sterilization, partner's vasectomy or intrauterine device.~* Chronic disease of the immune system, other than multiple sclerosis, which may require immunosuppressive treatment.~* Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c \> 8%.~* Active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.~* Previous treatment with cladribine, cyclophosphamide or mitoxantrone.~* Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months during the previous fingolimod study:~* Any of the following cardiovascular conditions that have developed during the previous fingolimod study:~  * Myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;~ * Cardiac failure (Class III, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator;~ * Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)~ * History or presence of a third degree AV block~ * Proven history of sick sinus syndrome or sino-atrial heart block~ * Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon~* Any of the following pulmonary conditions during the previous fingolimod study:~  * Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous fingolimod study)~ * Active tuberculosis~* Alcohol abuse, chronic liver disease during the previous fingolimod study.~The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5 mg/day (Type: EXPERIMENTAL): Open-label fingolimod 0.5 mg, taken orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of idiopathic Parkinson's disease (PD) by a neurologist~* Age more than 18 years~* Written informed consent given either by the patient or next of kin~* Patient on L-DOPA therapy~Exclusion Criteria:~* Patients with a diagnosis of secondary parkinsonism, and Parkinson's plus syndrome~* History of recent proton pump inhibitors (PPIs) or Histamine (H2) antagonist use for at least 4 weeks prior to the urea breath test~* History of recent antibiotics use (less than 6 months)~* Inability to perform urea breath test

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eradication therapy (Type: EXPERIMENTAL): The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has Moderate or Severe loss of jawline definition as determined by the EI using the ALJDs (Grade 2 or 3 on the ALJDS) on both sides. The grade does not have to be the same on both sides, but must be Grade 2 or 3~* Treating Investigator (TI) considers the subject's jaw amenable to an improvement of at least 1 grade on the scale for the jawline definition~* Written Informed Consent (IC) has been obtained~Exclusion Criteria:~* Has ever received permanent facial implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face or neck, or is planning to be implanted with any of these products during the study~* Has ever undergone fat injections in the malar, chin or jawline area or is planning to undergo this procedure during the study~* Has undergone semipermanent dermal filler treatment (eg, calcium hydroxyapatite, poly-L-lactic acid) below the subnasale within 36 months before enrollment or is planning to undergo such treatment during the study~* Has received deoxycholic acid treatment in the submental region in the last 6 months~* Has active autoimmune disease~* Females who are pregnant, nursing, or planning a pregnancy during the course of the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VOLUX XC (Type: EXPERIMENTAL): Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
- No-treatment control (Type: EXPERIMENTAL): No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis~* Body Mass Index (BMI) below or equal to 35.0 kg/m\^2~* Insulin naive subject and ongoing treatment with 1 or more oral antidiabetic drugs (OADs) for at least 12 weeks prior to randomisation with at least recommended maintenance dose according to local, approved labelling Allowed are: a. Previous short term insulin treatment up to 14 days; b. Treatment during hospitalization or during gestational diabetes is allowed for periods longer than 14 days)~Exclusion Criteria:~* Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers, mono amino oxidase (MAO) inhibitors~* Use of glucagon-like peptide-1 (GLP-1) receptor agonists, buformine and/or rosiglitazone within the last 12 weeks prior to randomisation~* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Before Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing thyroid surgery for benign disease~Exclusion Criteria:~* Depression~* Chronic pain disorder~* Insulin dependent diabetes mellitus~* History of PONV~* Pregnancy~* Age \< 18 years~* Received antiemetic therapy within 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A, 1 (Type: PLACEBO_COMPARATOR): Placebo 45 minutes prior to surgery
- A, 2 (Type: ACTIVE_COMPARATOR): 8 mg Dexamethasone 45 minutes prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 12 years and older~* Diagnosis of M. abscessus, including all subspecies, abscessus, bolleti, and massiliense lung disease according to the 2007 ATS/IDSA criteria~* Both newly diagnosed and currently on treatment or previously treated patients will be included~* Culture positive (either sputum or bronchoscopy) for M. abscessus at time of screening~* Willingness to adhere to a treatment regimen, study visits, and study procedures during the course of the study.~* Ability to produce at approximately 3.0 mL of sputum or be willing to undergo an induction that produces approximately 3.0 mL of sputum for culture collection~* Female of childbearing potential agrees to practice an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)~* Written informed consent or assent obtained from the patient, parent or legal guardian prior to the performance of any study related procedures~Exclusion Criteria:~* Active pulmonary tuberculosis requiring treatment at screening~* Treatment with inhaled or intravenous Amikacin within 14 days prior to baseline~* Known hypersensitivity to aminoglycosides~* Aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal or total bilirubin ≥ 2 times the upper limit of normal (ULN) at screening~* Current addiction to alcohol or illicit drug abuse~* Any condition which in the opinion of the Investigator interferes with ability to adhere to study requirements~* Primary immunodeficiency syndromes and acquired immunodeficiency syndromes (e.g., HIV-positive patients regardless of CD4 counts)~* Absolute neutrophil count ≤500/μL at Screening~* Significant (as determined by the investigator) hearing loss, vestibular dysfunction, neuromuscular weakness or a diagnosis of myasthenia gravis, where the potential risk of aminoglycoside toxicity outweighs the potential benefit~* Serum creatinine \>2 times ULN at Screening~* History of lung transplantation~* Any condition that, in the judgment of the Investigator, would compromise the ability of the subject to complete the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAI plus multi-drug regimen (Type: EXPERIMENTAL): once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions~* Male or female \>=40 years of age~* Has symptoms associated with OA of the index knee for at least 6 months prior to Screening~* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA~* Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee per Screening X-ray~* Index knee pain for \> 15 days over the last month~* Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)~* Body mass index (BMI) ≤ 40 kg/m2~* Willingness to abstain from use of restricted medications~Exclusion Criteria:~* Any condition that could possibly confound the patient's assessment of index knee pain in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back pain and hip pain that is referred to the knee that could cause misclassification, pain in any other area of the lower extremities or back that is equal or greater than the index knee pain)~* Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease~* History of infection in the index knee~* Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening~* Unstable joint within 12 months of screening~* IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening~* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening~* Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1 month of Screening~* Any other IA investigational drug/biologic within 6 months of Screening~* Prior use of FX006~* Women of child-bearing potential not using effective contraception or who are pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FX006 32mg (Type: EXPERIMENTAL): Single 5 mL intra-articular (IA) injection Extended-release Formulation
- Normal Saline (Type: PLACEBO_COMPARATOR): Single 5 mL intra-articular (IA) injection
- TCA IR 40 mg (Type: ACTIVE_COMPARATOR): Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* 18-49 years old~* Currently receiving HAART~* Belong to a patient support group or demonstrate willingness to join a support group.~* Have access to farming land and available surface water~* Have evidence of food insecurity, hunger and/or malnutrition (BMI\<18.5 kg) based on FACES medical records during the year preceding recruitment.~* Participants must also agree to save the down payment (\~$7) required for the loan, participate in the Adok Timo training.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Multi-sectoral agricultural intervention (Type: EXPERIMENTAL): Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
- Control (Type: NO_INTERVENTION): Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous Lidocaine During Sedation for Colonoscopy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* colonoscopy without gastroscopy~Exclusion Criteria:~* lidocaine allergy~* epilepsy~* severe heart rhythm disorders~* renal failure with creatinine clearance lower than 30ml/minute

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Administration of normal saline: same volume of saline as lidocaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese male or female, aged 18-55 years (both inclusive) at the time of signing informed consent.~* Body weight equal to or above 54.0 kg~* Body mass index (BMI) between 20.0 and 24.9 kg/m\^2 (both inclusive)~* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the screening visit, as judged by the investigator.~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods~* History of pancreatitis (acute or chronic) as declared by the subject.~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC) as declared by the subject.~* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) as declared by the subject.~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g., subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) as declared by the subject.~* Smoker (defined as a subject who is smoking equal to or more than 1 cigarette or the equivalent per day).~* Unable or unwilling to refrain from smoking and use of nicotine substitute products during the inpatient periods, as judged by the investigator.~* Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Oral semaglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Smokers smoking at least 15 cigarettes/day as a mean within the 2 months preceding the screening visit~* Motivated to quit with a score greater than or equal to 6 on the ten-point Motivation Scale~Exclusion Criteria:~* non tobacco cigarettes consumption~* chronic use of marijuana~* pregnancy~* breastfeeding~* any clinically significant disease that might interfere with the efficacy or safety evaluation of the study drug~* Concomitant use of drugs as an aid to smoking cessation or that might induce weight change

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Group-Based Walking Study Using WeChat to Enhance Physical Activity Among Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are 60 or older who have a cellphone, with either android or iPhone system with data plan.~* They must be fit enough to walk for at least 20 minutes at a time.~* English speaking~Exclusion Criteria:~* Unable to walk more than 20 minutes;~* do not have smart phone with data plan.~* younger than 60

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Condition (Type: EXPERIMENTAL): Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
- Treatment condition (Type: EXPERIMENTAL): Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pentazocine on Manic Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Young Mania Rating Scale (YMRS) greater than 14~* Inpatient~Exclusion Criteria:~* History of opiate abuse/dependence~* Recent history of substance abuse~* Pregnancy~* Unstable medical issues~* Use of opiate medications for pain management

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Pentazocine/Talwin (Type: EXPERIMENTAL): Talwin NX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete